Abstract Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and numerous internal organs and a severe fibroproliferative vasculopathy resulting frequently in severe disability and high mortality. Although the etiology of SSc is unknown and the detailed mechanisms responsible for the fibrotic process have not been fully elucidated, one important observation from a large US population study was the demonstration of a late onset of SSc with a peak incidence between 45 and 54 years of age in African-American females and between 65 and 74 years of age in white females. Although it is not appropriate to consider SSc as a disease of aging, the possibility that senescence changes in the cellular elements involved in its pathogenesis may play a role has not been thoroughly examined. The process of cellular senescence is extremely complex, and the mechanisms, molecular events, and signaling pathways involved have not been fully elucidated; however, there is strong evidence to support the concept that oxidative stress caused by the excessive generation of reactive oxygen species may be one important mechanism involved. On the other hand, numerous studies have implicated oxidative stress in SSc pathogenesis, thus, suggesting a plausible mechanism in which excessive oxidative stress induces cellular senescence and that the molecular events associated with this complex process play an important role in the fibrotic and fibroproliferative vasculopathy characteristic of SSc. Here, recent studies examining the role of cellular senescence and of oxidative stress in SSc pathogenesis will be reviewed.
Introduction
Systemic sclerosis (SSc) is a systemic autoimmune disease of unknown etiology characterized by progressive fibrosis of skin and numerous internal organs and a severe fibroproliferative vasculopathy resulting frequently in functional disability and high mortality [1] [2] [3] . The pathogenesis of SSc is complex, and despite numerous studies that have examined its intricate picture, the exact mechanisms involved in the severe cutaneous and systemic fibrotic process have not been fully elucidated [4] [5] [6] [7] . One important demographic feature identified in a large SSc population is that SSc disease onset and its peak incidence occur between the ages of 45 and 54 years for African-American women and between the ages of 65 and 74 years for white women [8] . The reasons for the late onset and higher frequency of SSc in individuals older than 45 years of age are not known and have not been examined in detail. Although it is not appropriate to consider SSc as a disease of aging, the possible role of cellular senescence in SSc pathogenesis should be considered as an important factor. Among the reactions or pathways that may be involved in this process, there is strong evidence that oxidative stress mediated by an excessive generation of reactive oxygen species (ROS) plays a crucial role. We will review here recent experimental evidence supporting the participation of cellular senescence and oxidative stress in SSc pathogenesis, emphasizing the potential role of oxidative stress in the fibrotic process that is the hallmark of SSc. We will also discuss recent evidence indicating that the NADPH oxidase NOX4 may be one of the most important mediators of ROS generation in SSc and the potentially beneficial effects of inhibition of NOX4 activity as a cogent therapeutic approach for SScassociated tissue fibrosis and fibroproliferative vasculopathy.
Cellular Senescence and SSc Pathogenesis
Cellular Senescence and Senescence-Associated Secretory Phenotype Cellular senescence, a process first identified by Hayflick and Moorehead in their pioneering studies on human diploid fibroblasts cultured in vitro [9, 10] , is characterized by the permanent arrest of cell division associated with a variety of phenotypic changes including cellular enlargement, flattening, and vacuolization, as well as numerous functional alterations [reviewed in [11] [12] [13] [14] [15] [16] . The most prominent of these alterations are the expression of novel specific gene products such as the senescence-associated β-galactosidase isoform (SA-βgal), and the acquisition of a unique complement of secreted molecules which includes inflammatory cytokines and chemokines, growth factors, and various proteases and other pro-inflammatory molecules collectively known as the senescence-associated secretory phenotype or SASP [17••, 18-21] . The most important pro-inflammatory and profibrotic SASP components are listed in Table 1 . Although it was initially considered that cellular senescence may be solely a protective mechanism to prevent the uncontrolled cellular proliferative activity of malignant cells, extensive studies have demonstrated that it may participate in numerous physiological processes including embryonic development [22••, 23 ••], as well as in pathologic conditions associated with aging [11-13, 24, 25] .
The mechanisms responsible for the irreversible arrest in cellular proliferative capacity are highly complex, and although they have been studied extensively, they have not been fully elucidated. However, it has been shown that a variety of stimuli and numerous signaling pathways may be involved [11-13, 16, 18] . The most important triggers of cellular senescence are the activation of the DNA damage response (DDR) initiated by the occurrence of structural changes in DNA and complex molecular events involving oncogene effects; abnormalities in cell cycle kinases, including various cyclin-dependent kinases; and telomere shortening or dysfunction [11] [12] [13] [26] [27] [28] . Of relevance to the topic of this review are the extensive observations demonstrating that two important mechanisms involved in cellular senescence are ROS-induced oxidative stress [29] [30] [31] [32] [33] [34] and persistent stimulation by type I interferons [35] [36] [37] .
Cellular Senescence and SSc
There has been strong interest in the role of cellular senescence in malignancies and disorders of aging; however, there is very little information about its possible contribution to SSc pathogenesis. Among the few investigations that have explored the possible connection between senescence, aging, and SSc, a recent study conducted an evaluation of normal fibroblasts obtained from donors of various ages (up to 33 years of age) and of several dermal fibroblast cell strains obtained from patients with SSc employing a proteomic approach [38••] . The study identified numerous age-dependent differences including the accumulation of SA-βgal and showed that SSc fibroblasts displayed evidence indicative of cellular senescence and decreased autophagy. Another study [39] examined bone marrow-derived mesenchymal stem cells from SSc patients and demonstrated that these cells displayed markers of early senescence and had an impairment in their ability to differentiate into endothelial cells, suggesting that these alterations may be important for the pathogenesis of the vascular involvement in SSc.
Numerous studies have examined alterations in telomere length as playing a role in the development of various autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, SSc, and Sjögren's syndrome; however, the available evidence is not conclusive and may be even contradictory in some studies [40, 41] . There are very few studies of telomere length in SSc [42] [43] [44] . Although an early study described that telomere length was significantly shortened in SSc patients and suggested that this observation may be either reflective of a genetic predisposition to chromosomal instability or the result of exposure to a noxious environmental agent [42] , a more recent study described contradictory results demonstrating that telomere length was longer in peripheral blood mononuclear cells from SSc patients [44] . Therefore, the original description of shortened telomeres in cells from SSc patients requires further experimental validation. In this respect, a study of telomerase activity in peripheral blood mononuclear cells from patients with various autoimmune diseases demonstrated that in contrast with cells from patients with rheumatoid arthritis and systemic lupus erythematosus that displayed elevated activity of the enzyme, cells from SSc patients had remarkably low levels of telomerase activity [45] . However, the significance of this observation to SSc pathogenesis has not been elucidated.
Although not directly related to SSc pathogenesis, several studies of another fibrotic disease that displays a clear pattern of increased occurrence in older individuals, namely idiopathic pulmonary fibrosis (IPF), have provided evidence to support the notion that cellular senescence may play an important role in its pathogenesis [46] [47] [48] . Indeed, recent studies showed an unexpectedly high frequency of telomerase mutations and telomere shortening in a large population of patients affected with the familial form of IPF [49, 50] .
Caveolin-1 and PTEN in Cellular Senescence
Strong experimental evidence has demonstrated that caveolin-1 (cav-1), the protein responsible for the remarkable functional properties of caveolae, is decreased in affected cells and tissues from SSc or IPF patients [51] [52] [53] [54] . Numerous recent studies have shown that cav-1 plays an important role in the pathophysiology of tissue fibrosis [51, 52, 55 ••], most likely owing to its ability to induce internalization of activated TGF-β receptors into cav-1 lipid rafts leading to their rapid proteasomal degradation [52, 55••] . Although an earlier study indicated that expression of cav-1 induced premature cellular senescence in primary cultures of murine fibroblasts [56] , and a more recent investigation demonstrated that cav-1 deficiency protects from bleomycin-induced pulmonary fibrosis in mice [57] , recent evidence indicates that cav-1 exerts antifibrotic effects by modulating the activity of the phosphatase and tensin homolog (PTEN). PTEN is a tumor suppressor protein that has been implicated in cellular senescence. A recent study found that PTEN was markedly decreased in lung fibroblasts from IPF patients as well as in lungs from mice with bleomycin-induced pulmonary fibrosis and that this reduction was mediated by decreased cav-1 [58] . In light of previous studies demonstrating that a reduction of PTEN exerted potent pro-fibrotic effects in vitro and in vivo [59] , the newly uncovered interaction between cav-1, PTEN, and cellular senescence represents a novel pro-fibrotic mechanism that may be of relevance to SSc pathogenesis.
ROS and Oxidative Stress in SSc Pathogenesis

Evidence of Oxidative Stress in SSc
In 1993, Murrell proposed a unifying hypothesis to explain the pathogenesis of the cutaneous fibrotic process in a variety of systemic fibrotic disorders including SSc, suggesting a crucial role for oxygen free radical-induced oxidative stress [60] . Following this report, numerous studies have provided experimental support for this hypothesis and explored the mechanisms involved [reviewed in [61] [62] [63] . It has been shown that oxidative stress in SSc is the result of an imbalance between the production of oxidative stress-producing systems and their antagonist antioxidant mechanisms. Increased generation or overproduction of ROS appears to be the main mechanism whereas ROS inactivation plays a less important role. Although one recent study demonstrated increased levels of antioxidants in serum of about 25 % of SSc patients as measured by a total antioxidant power assay [64••] , numerous other studies have shown increased ROS production by various cells in SSc, as well as elevated levels in plasma from SSc patients [65••, 66-69] , providing strong evidence for the important contribution of oxidative stress in SSc pathogenesis. A recent study compared the total oxidant status (TOS), total antioxidant status (TAS), and an oxidative stress index (OSI) between SSc patients and healthy volunteers. The results demonstrated that TOS and OSI levels were significantly higher in SSc patients than in controls, whereas there were no significant differences in TAS between the two groups [65••] . These results indicated a remarkable imbalance CCL5 chemokine (C-C motif) ligand, CXCL chemokine (C-X-C motif) ligand, GRO growth-related oncogene, HGF hepatocyte growth factor, IGFBP insulin-like growth factor-binding protein, MCP monocyte chemoattractant protein, MIF macrophage migration inhibitory factor, MIP macrophage inflammatory protein, MMP matrix metalloproteinase, NAP2 NF-κB-activating gene 2, OPGN osteoprotegerin, OSM oncostatin M, PLGF placenta growth factor, SASP senescence-associated secretory phenotype, TIMP tissue inhibitor of metalloproteinases, TRAIL tumor necrosis factor-related apoptosis-inducing ligand between the profoundly increased oxidative stress levels and the relatively insufficient antioxidant status in SSc. In agreement with these observations, elevated levels of various oxidative stress-related products have been detected in various biological fluids from SSc patients including increased urinary 8-oxodG levels [70] and increased levels of isoprostanes in SSc serum [71, 72] , in the urine [73, 74] , or in exhaled breath [75] . Isoprostanes such as F2-isoprostanes are markers of lipid peroxidation [76] , produced in vivo in humans by free radicalcatalyzed peroxidation of arachidonic acid. Other markers of oxidative stress in SSc include increased serum levels of N(epsilon)-(hexanoyl)lysine [77] and elevated serum levels of heat shock protein 70 [78] . The functional relevance of the elevated oxidative stress components in the circulation of SSc patients was evidenced in one recent study showing that sera from patients with SSc pulmonary hypertension caused oxidative stress-induced activation of collagen synthesis in human pulmonary smooth muscle cells [79] .
Role of ROS in SSc Fibrosis and Fibroproliferative Vasculopathy
ROS are a group of oxygen-derived molecules characterized by high chemical reactivity. It has been recently recognized that under physiological conditions, ROS play important functions in intracellular signaling by activating redox-sensitive pathways including the cellular responses to growth factor stimulation and the establishment of inflammatory responses [reviewed in [80] [81] [82] . However, in pathological states, higher ROS levels can induce oxidative stress causing damage to proteins, lipids, and DNA, as well as inducing cellular senescence as discussed above. Following Murrell's provocative hypothesis linking SSc pathogenesis to the deleterious effects of ROS [60] , numerous studies have implicated excessive oxidative stress and the generation of deleterious ROS in the pathogenesis of SSc [reviewed in [61] [62] [63] . The studies of Sambo et al. [69] provided elegant experimental evidence that SSc dermal fibroblasts produce increased levels of ROS compared with normal cells and that the elevated ROS may be involved in the increased expression of a pro-fibrotic phenotype in these cells. The same group also demonstrated that monocytes from SSc patients spontaneously release increased amounts of superoxide anions in vitro [66] . Other studies supporting the role of ROS in the development of the fibrotic and vasculo-proliferative lesions in SSc include the induction of high production of ROS by endothelial cells and fibroblasts in vitro following exposure to sera from SSc patients [68] and in pulmonary artery smooth muscle cells exposed to serum from SSc patients with pulmonary hypertension [79] , as well as the ROS-mediated inhibition of the anti-Wnt protein Wnt inhibitory factor 1 (WIF-1) leading to activation of Wnt pathway-induced tissue fibrosis [83••] . Another study described a dose-dependent abrogation of the increased production and secretion of type I collagen and fibronectin characteristic of SSc fibroblasts following in vitro exposure to the potent antioxidant epigallocatechin-3-gallate (EGCG). EGCG also reduced the expression of the fibrotic marker CTGF, inhibited collagen gel contraction, and suppressed intracellular ERK1/2 kinase signaling and NF-κB activity [84••] .
Although the detailed mechanisms involved in ROS effects in induction and establishment of the fibrotic process in SSc have not been fully elucidated, there is intense ongoing research exploring various novel directions. Among these, one recent study described a novel mechanism by which ROS may promote a pro-fibrotic phenotype in SSc fibroblasts [85••] . This mechanism involves the ROS-mediated oxidative inactivation of protein tyrosine phosphatase 1B (PTP1B) leading to pronounced platelet-derived growth factor receptor (PDGFR) activation. In this study, PTP1B activity was significantly reduced in SSc fibroblasts, most likely as a result of increased cysteine oxidation caused by higher levels of ROS. Confirmation of the important role of PTP1B on the regulation of the fibrotic process was obtained from studies showing that decreased PTP1B expression in normal fibroblasts led to increased expression of the genes encoding type I collagen and to elevated production of the corresponding protein [85••] .
NADPH Oxidases
The NADPH oxidase (NOX) family of membrane-associated enzymes catalyzes the reduction of O 2 to form ROS. The crucial roles of NOX in normal cellular physiology are evidenced by the remarkable increase in the number of NOX isoforms during eukaryotic evolution and their striking conservation through multiple species [86, 87] . Several biochemical processes and enzyme systems are capable of producing ROS in vivo; however, the NOX are the primary enzymes responsible for inducible ROS formation [reviewed in [88] [89] [90] . The role of NOX enzymes in a variety of human disorders is currently the focus of intense investigation, and numerous studies have provided strong experimental evidence to support their participation in a variety of pathologic conditions. Currently, seven distinct NOX isoforms have been identified in humans and there are substantial differences in their tissue distribution; however, several of them display prominent expression in tissues and cells of substantial relevance to the pathophysiology of SSc. The three most important NOX isoforms related to SSc are NOX1, NOX2, and NOX4. Although the highest expression levels of NOX1 are in colonic epithelium, this isoform is also abundantly expressed in endothelial cells and vascular smooth muscle cells. NOX2 is the classic inflammatory isoform found in neutrophils and macrophages but is also expressed in B lymphocytes and in endothelial cells. NOX4 is highly expressed in the kidneys; however, it displays very high expression in fibroblasts, smooth muscle cells, and endothelial cells as well as in the lung.
Role of NOX4 in Tissue Fibrosis
Numerous recent studies have shown that NOX4 is a crucial molecule involved in the initiation, establishment, and development of tissue fibrosis. Indeed, multiple growth factors and related polypeptides which participate in SSc pathogenesis [4] [5] [6] [7] including TGF-β, the most potent cytokine implicated in the fibrotic process, as well as other pro-fibrotic polypeptides including PDGF, angiotensin II, and endothelin-1 have been shown to modulate the expression of NOX and, in particular, that of NOX4. Stimulation of NOX4 expression by TGF-β has been demonstrated in numerous recent studies [91] [92] [93] . PDGF, angiotensin II, and endothelin-1 have also been shown to induce increased NOX4 expression [94] [95] [96] . NOX4 has been identified as a source of ROS responsible for the generation and activation of TGF-β-induced pulmonary, cardiac, and renal myofibroblasts in vitro [91] [92] [93] [97] [98] [99] [100] [101] [102] . NOX4 is upregulated in lungs of patients with IPF and in kidney and liver fibrosis [99, 103, 104] . NOX4-dependent generation of ROS has been postulated to be involved in the fibrotic process in SSc [105, 106] ; however, experimental evidence in support of this hypothesis is still lacking. Of great relevance to the role of NOX4 in the pathogenesis of the fibroproliferative vasculopathy in SSc is a recent study demonstrating that ROS were capable of inducing the phenotypic conversion of endothelial cells into activated myofibroblasts through a TGF-β-dependent mechanism [107••] .
Regulation of NOX4 Activity
The mechanisms involved in the regulation of NOX activity are quite complex, and it is likely that they vary depending on a specific cellular and functional context. However, it is important to emphasize that, in contrast with all other NOX enzymes, NOX4 does not require other protein subunits for its activity and, therefore, the levels of its activity are dependent on the levels of expression of its corresponding gene [108] . Given the important functions of NOX4 in a variety of physiological processes and in the pathogenesis of numerous diseases, there has been intense interest in unveiling the intimate mechanisms of its regulation. The mechanisms of increased NOX4 expression by TGF-β are the focus of intense investigation [109, 110] . A recent study identified a far upstream AP-1/Smad-binding element in the human NOX4 promoter that was involved in the regulation of NOX4 expression by TGF-β [109] .
Regarding the regulation of NOX4 activity, one important mechanism has been recently recognized. This study demonstrated a novel and quite important interaction of NOX4 with the polymerase delta-interacting protein 2 (PDIP2) that resulted in a threefold stimulation of NOX4 activity by PDIP2 [111••] . The full significance of this important discovery is still not apparent but undoubtedly represents a promising novel area for further investigation. Although the exact mechanisms involved in the regulation of NOX4 levels in normal cells are becoming unveiled, the possible alterations responsible for the constitutive elevation in NOX4 levels and activity in SSc cells have not been studied.
NOX4 Inhibitors as a Potential Antifibrotic Therapeutic Intervention
Following Murrell's provocative hypothesis [60] , numerous studies have provided strong supporting evidence for a role of ROS in abnormal, exaggerated fibrogenesis and for the therapeutic targeting of ROS in fibrotic disorders such as SSc [112] . Indeed, a plethora of clinical studies have examined a variety of pharmacological or naturally occurring antioxidant compounds as potential therapeutic agents for various aspects of the complex clinical manifestations of SSc [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] . Most of the clinical studies examining the effects of antioxidant therapy for SSc including some large placebo-controlled clinical trials [122] have not provided conclusive evidence of a therapeutical benefit. However, the recent demonstration of the crucial role of NOX4 in the generation of ROS and the development of highly selective small-molecule inhibitors [ •] demonstrated remarkable differences in the extent and severity of bleomycin-induced pulmonary fibrosis induced in young mice compared to aged mice. These differences were caused by a NOX4-induced senescence phenotype in fibroblasts from the aged animals that prevented fibrosis resolution by rendering these cells resistant to apoptosis. The results demonstrated that persistent lung fibrosis in aging was mediated by NOX4-induced oxidative stress that resulted in cellular senescence and the acquisition of an apoptosis-resistant fibroblast phenotype. A remarkable observation was the reversal of this phenotype following treatment with the NOX4-selective small-molecule inhibitor GKT137831.
Although the extensive investigational studies reviewed above have suggested that specific or selective NOX4 inhibitors may be of benefit for the therapy of SSc patients, their beneficial effects need to be conclusively demonstrated in rigorously controlled clinical trials.
Cellular Senescence and Oxidative Stress Pathways Leading to Tissue Fibrosis in SSc
The causative agent or events and the exact mechanisms responsible for SSc development remain unknown. However, extensive recent information about cellular senescence and oxidative stress suggest a cogent hypothesis that may explain numerous observations obtained from the study of SSc cells and tissues. This hypothesis postulates that the potent profibrogenic growth factor TGF-β becomes activated following its release from the latent TGF-β binding protein and engages its cognate receptors in the surface of TGF-β-responsible cells. The sequence of events resulting from active TGF-β receptor engagement leads to the upregulation of expression of NOX4 mediated by the canonical Smad pathway, although other non-canonical TGF-β signaling pathways may be involved as well. Owing to the fact that NOX4 does not require additional cofactors and that its activity is largely determined by the levels of protein expression, the TGF-β-induced increase in NOX4 transcript levels results in increased NOX4-mediated ROS production. Elevated ROS production would then initiate a cascade of events leading to the establishment of an autocrine and paracrine self-stimulating pathway responsible for the progressive fibrotic process in SSc. The main components of the autocrine/paracrine loop induced by elevated ROS levels include the following:
1. Further release of TGF-β from the latent TGF-β complex. 2. Intracellular activation of TGF-β-dependent signaling pathways leading to the activation of quiescent fibroblasts and the induction of the myofibroblast phenotype in these cells, as well as in endothelial cells through the process of endothelial to mesenchymal transition. The activated myofibroblasts are the cells ultimately responsible for the fibrotic process in SSc. TGF-β also causes downregulation of genes encoding for antifibrotic proteins such as cav-1 and PTEN or MMPs and other extracellular matrix (ECM)-degrading enzymes. Reduction of cav-1 and PTEN is also involved in stimulation of cellular senescence as well as in stimulation of the profibrotic phenotype. 3. ROS-mediated initiation and maintenance of cellular senescence. This is one of the crucial components of the pathway initiated by ROS-mediated oxidative stress in the target cells that results in tissue fibrosis. Although other mechanisms that cause cellular senescence such as DDR or telomere shortening may also be involved, oxidative stress, an important initiating event of cellular senescence, is induced by elevated ROS levels. 4. The establishment of cell senescence in the target cells is accompanied by profound structural and molecular changes including the expression of SASP and the secretion of multiple pro-inflammatory and pro-fibrotic molecules (Table 1) . 5. The multiple components of the SASP exert potent effects on a variety of cells that are involved in SSc pathogenesis including fibroblasts, endothelial cells, and monocytes. 6. Cytokines and growth factors present in the SASP induce quiescent fibroblasts to become activated and to acquire the pro-fibrotic phenotype of activated myofibroblasts. These cells produce exaggerated levels of various ECM macromolecular components and also display reduced expression and secretion of relevant metalloproteinases and other proteases capable of degradation of ECM components. 7. The endothelial cells present in the microvasculature in proximity to the senescent cells are also induced by SASP components to change their phenotype and become activated myofibroblasts through endothelial to mesenchymal cellular transdifferentiation processes. 8. Monocytes are attracted from the circulation through the effects of various cytokines and chemokines present in the SASP and become activated. Following their activation, macrophages are induced to change their phenotype into pro-fibrotic M2 macrophages which then establish a chronic inflammatory infiltrate in the affected tissues. 9. The activated M2 macrophages can directly contribute to the fibrotic process through the production and secretion of pro-fibrotic cytokines and growth factors causing further stimulation of ECM production as well as, by enhancing the activation of quiescent fibroblasts into myofibroblasts and by inducing the endothelial to mesenchymal transition of endothelial cells. 10. The activated macrophages also contribute to the establishment of a vicious cycle mediated by the macrophage production of TGF-β, and interferons and related macromolecules. The macrophage production of TGF-β can induce further NOX4 production, and the interferon and related peptides can reenforce the process of cellular senescence, thus allowing the establishment of an autocrine and paracrine self-sustaining mechanism that leads to tissue fibrosis. The individual components of the selfstimulating pathway and their interactions are illustrated in Fig. 1 .
Conclusion
There is strong experimental evidence supporting the concept that cellular senescence and ROS-mediated oxidative stress play a crucial role in the initiation, establishment, and the progression of fibrosis in SSc and that these effects appear to involve NOX4. Therefore, the potential use of specific NOX4 inhibitors for the treatment of SSc would be expected to be an effective therapeutic approach. Although numerous clinical studies have examined the potentially beneficial effects of various therapeutic interventions aimed at the reduction of oxidative stress for SSc, the results have not conclusively shown therapeutic effectiveness. Therefore, it will be necessary to perform in vitro studies with specific or selective small-molecule or peptide NOX4 inhibitors followed by well-designed placebo-controlled clinical trials to document The components of the SASP induce phenotypic changes in fibroblasts (6), endothelial cells (7), and monocytes (8) . The monocytes become activated M2 profibrotic macrophages that further increase the fibrotic process (9). 10 The activated macrophages produce and secrete TGF-β and interferons and various interferon-related molecules. The secreted TGF-β and interferon-related products close the vicious cycle and allow establishment of an autocrine/paracrine pathway that is responsible for the initiation and progression of tissue fibrosis in SSc conclusively any beneficial effects. Furthermore, clinical trials should also consider evaluating the use of NOX4 inhibitors in combination with other drugs modulating different pathways of the complex pathogenesis of SSc as this multidrug approach may result in improved therapy for this disabling and frequently fatal disease.
